SCSiobhan Cross

Siobhan Cross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Siobhan Cross has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimising Asparaginase Use and Managing Hypersensitivity in A ustralasia—A Clinical Practice Guideline From the A ustralian and N ew Z ealand Children's Haematology/Oncology Group

    by Matthew J. O'COnnor, Michelle Martin, Sarah M. Trinder, Draga Barbaric, Diane Hanna, Chow Y. Lai, Michael P. Osborn, Tim Prestige, Bryony Ross, Leanne Super, et al.

    Background: Asparaginase is a critical component of modern multi‐agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. Objectives: To develop a clinical practice guideline for the use of asparaginase products in the Australasian context. Methods: This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region. Results: This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion. Conclusions: This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.

  • Open Access

    Psychosocial Outcomes in Parents of Children with Acute Lymphoblastic Leukaemia in Australia and New Zealand Through and Beyond Treatment

    by Clare Parker, Clarissa E. Schilstra, Karen McCleary, Michelle Martin, Toby N. Trahair, Rishi S. Kotecha, Shanti Ramachandran, Ruellyn Cockcroft, Rachel Conyers, Siobhan Cross, et al.

    Background/Objectives: Parents of children with acute lymphoblastic leukaemia (ALL) experience emotional distress throughout their child’s treatment course. This study describes the psychological experience of Australian and New Zealand parents of children diagnosed with ALL. Methods: This prospective, longitudinal study assessed distress, anxiety, depression, anger and the need for help in parents of children with newly diagnosed ALL across eight sites between October 2018 and November 2022. Psychological symptoms were quantified using the Emotion Thermometer (ET) tool and Patient-Reported Outcome Measurement Information System (PROMIS) questionnaires. Participants were recruited within ninety days of chemotherapy commencement, with surveys distributed bimonthly thereafter. Results: One hundred and seventeen participants completed 327 survey responses spanning 0 to 62 months post-diagnosis. Parental distress peaked within the first 6 months and 40% of parents reported clinically significant symptoms across four or more domains as measured by our questionnaires. Anxiety was the most consistently elevated symptom, with over 50% of responses above the clinical cut-off. Depression and the need for help also peaked closer to diagnosis and declined over time. In contrast, anger remained stable, with 27% reporting clinically significant scores across all time points. Increased time since diagnosis was significantly associated with reductions in distress, anxiety and depression scores. Conclusions: Australian and New Zealand parents experience high levels of psychological distress within the first six months following their child’s diagnosis of ALL. A notable minority continue to report elevated distress levels over time, identifying a need for improved psychological support for family wellbeing throughout the ALL treatment trajectory.


  • Open Access

    Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group

    by Denitza Mironova, Chitra M. Saraswati, Peter Downie, Chow Yee Lai, Eleanor Cook, Vickyanne Carruthers, Perla Moukhaiber, Fiona Molloy, Joshua Serov, Elizabeth McKinnon, et al.


  • Open Access

    Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

    by Nicola C. Venn, Libby Huang, Lenka Hovorková, Walter Muskovic, Marie Wong, Tamara Law, Susan L. Heatley, Seong Lin Khaw, Tom Revesz, Luciano Dalla Pozza, et al.

    Background: ABL-class fusions including NUP214-ABL1 and EBF1-PDGFRB occur in high risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to BCR-ABL-positive ALL. Our aim was to evaluate new DNA-based measurable residual disease (MRD) tests detecting these fusions and IKZF1-deletions in comparison with conventional immunoglobulin/T-cell receptor (Ig/TCR) markers. Methods: Precise genomic breakpoints were defined from targeted or whole genome next generation sequencing for ABL-fusions and BCR-ABL1. Quantitative PCR assays were designed and used to re-measure MRD in remission bone marrow samples previously tested using Ig/TCR markers. All MRD testing complied with EuroMRD guidelines. Results: ABL-class patients had 46% 5year event-free survival and 79% 5year overall survival. All had sensitive fusion tests giving high concordance between Ig/TCR and ABL-class fusion results (21 patients, n = 257 samples, r2 = 0.9786, P < 0.0001) and Ig/TCR and IKZF1-deletion results (9 patients, n = 143 samples, r2 = 0.9661, P < 0.0001). In contrast, in BCR-ABL1 patients, Ig/TCR and BCR-ABL1 tests were discordant in 32% (40 patients, n = 346 samples, r2 = 0.4703, P < 0.0001) and IKZF1-deletion results were closer to Ig/TCR (25 patients, n = 176, r2 = 0.8631, P < 0.0001). Conclusions: MRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for IKZF1-deletions is feasible and provides good alternatives to Ig/TCR tests to monitor MRD in ABL-class ALL.


  • Open Access

    21 Lactate dehydrogenase‐B is silenced by promoter hypermethylation in human prostate cancer

    by J.W.F. Catto, S. Cross, J. Phillips, A. Leiblich, H. Leung, F.C. Hamdy, I. Rehman

    In order to identify novel candidates associated with prostate cancer metastasis, we compared the proteomic profile of the poorly metastatic human prostate cancer cell line LNCaP, with its highly metastatic variant LNCaP‐LN3, by two‐dimensional gel electrophoresis. A major protein spot (pI of 5.9 and molecular weight of 37 KDa) was seen in LNCaP cells, but not in LNCaP‐LN3 cells and was identified as Lactate dehydrogenase‐B ( LDHB ), by tandem mass spectrometry. Furthermore, enzyme kinetic assays and Zymography showed a higher LDH enzyme activity in LNCaP cells compared with LNCaP‐LN3. Bisulfite modified DNA sequencing showed promoter hypermethylation in LNCaP‐LN3 cells but not in LNCaP, Du145, PC3, CWR22 or BPH45 cells. Treatment of LNCaP‐LN3 cells with 5’‐azacytidine caused re‐expression of LDHB transcripts. In tissues, LDHB promoter hypermethylation occurred at a higher frequency in prostate cancer 14/31 (45%), compared to adjacent non‐malignant or benign tissue, 2/19 (11%), ( P < 0.025). Immunohistochemistry showed a higher frequency of LDHB expression in benign or non‐malignant tissues, 59/ 73 (81%), compared to cancer cases, 3/53 (6%), ( P < 0.001). Absent LDHB expression was also seen in 7/7 (100%) cases of metastatic cancer in bone. Our data are the first to show loss of LDHB expression in prostate cancer, the mechanism of which appears to involve promoter hypermethylation.